# A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

Source: https://onco.cc/trials/nct06943833/  
OnCo record `nct06943833` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Volrustomig in cervical cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) is a phase 2 interventional study registered as NCT06943833 by AstraZeneca, with 37 participants enrolled, started 2025-03-31 and due to reach its primary completion in 2028-03-13. Interventions recorded: Volrustomig.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06943833
- Phase: 2
- Setting: A Phase II Single-arm Multi-centre Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum Based, Concurrent Chemoradiation Therapy
- Sponsor: AstraZeneca
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT06943833: https://clinicaltrials.gov/study/NCT06943833

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06943833.json